139 related articles for article (PubMed ID: 24690205)
21. Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment.
De Rosa M; Paesano L; Nuzzo V; Zarrilli S; Del Puente A; Oriente P; Lupoli G
J Endocrinol Invest; 2001 Apr; 24(4):246-52. PubMed ID: 11383911
[TBL] [Abstract][Full Text] [Related]
22. Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Shimon I; Eshed V; Doolman R; Sela BA; Karasik A; Vered I
Osteoporos Int; 2005 Dec; 16(12):1591-6. PubMed ID: 16362147
[TBL] [Abstract][Full Text] [Related]
23. Effects of testosterone replacement in hypogonadal men.
Snyder PJ; Peachey H; Berlin JA; Hannoush P; Haddad G; Dlewati A; Santanna J; Loh L; Lenrow DA; Holmes JH; Kapoor SC; Atkinson LE; Strom BL
J Clin Endocrinol Metab; 2000 Aug; 85(8):2670-7. PubMed ID: 10946864
[TBL] [Abstract][Full Text] [Related]
24. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis.
Diamond T; Stiel D; Posen S
J Bone Miner Res; 1991 Jan; 6(1):39-43. PubMed ID: 2048430
[TBL] [Abstract][Full Text] [Related]
25. The effect of hypogonadism and testosterone-enhancing therapy on alkaline phosphatase and bone mineral density.
Dabaja AA; Bryson CF; Schlegel PN; Paduch DA
BJU Int; 2015 Mar; 115(3):480-5. PubMed ID: 25046796
[TBL] [Abstract][Full Text] [Related]
26. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.
Wang C; Eyre DR; Clark R; Kleinberg D; Newman C; Iranmanesh A; Veldhuis J; Dudley RE; Berman N; Davidson T; Barstow TJ; Sinow R; Alexander G; Swerdloff RS
J Clin Endocrinol Metab; 1996 Oct; 81(10):3654-62. PubMed ID: 8855818
[TBL] [Abstract][Full Text] [Related]
27. Chronic spinal and oral morphine-induced neuroendocrine and metabolic changes in noncancer pain patients.
Valverde-Filho J; da Cunha Neto MB; Fonoff ET; Meirelles Ede S; Teixeira MJ
Pain Med; 2015 Apr; 16(4):715-25. PubMed ID: 25521923
[TBL] [Abstract][Full Text] [Related]
28. Quantitative bone SPECT in young males with delayed puberty and hypogonadism: implications for treatment of low bone mineral density.
Lubushitzky R; Front D; Iosilevsky G; Bettman L; Frenkel A; Kolodny GM; Israel O
J Nucl Med; 1998 Jan; 39(1):104-7. PubMed ID: 9443746
[TBL] [Abstract][Full Text] [Related]
29. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids.
Rajagopal A; Vassilopoulou-Sellin R; Palmer JL; Kaur G; Bruera E
Cancer; 2004 Feb; 100(4):851-8. PubMed ID: 14770444
[TBL] [Abstract][Full Text] [Related]
30. Role of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndrome.
Ferlin A; Selice R; Di Mambro A; Ghezzi M; Di Nisio A; Caretta N; Foresta C
Osteoporos Int; 2015 Aug; 26(8):2193-202. PubMed ID: 25963234
[TBL] [Abstract][Full Text] [Related]
31. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome.
Rodriguez-Tolrà J; Torremadé J; di Gregorio S; Del Rio L; Franco E
Andrology; 2013 Jul; 1(4):570-5. PubMed ID: 23686863
[TBL] [Abstract][Full Text] [Related]
32. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.
Amory JK; Watts NB; Easley KA; Sutton PR; Anawalt BD; Matsumoto AM; Bremner WJ; Tenover JL
J Clin Endocrinol Metab; 2004 Feb; 89(2):503-10. PubMed ID: 14764753
[TBL] [Abstract][Full Text] [Related]
33. Effect of testosterone replacement on trabecular architecture in hypogonadal men.
Benito M; Vasilic B; Wehrli FW; Bunker B; Wald M; Gomberg B; Wright AC; Zemel B; Cucchiara A; Snyder PJ
J Bone Miner Res; 2005 Oct; 20(10):1785-91. PubMed ID: 16160736
[TBL] [Abstract][Full Text] [Related]
34. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women.
Fraser LA; Morrison D; Morley-Forster P; Paul TL; Tokmakejian S; Larry Nicholson R; Bureau Y; Friedman TC; Van Uum SH
Exp Clin Endocrinol Diabetes; 2009 Jan; 117(1):38-43. PubMed ID: 18523930
[TBL] [Abstract][Full Text] [Related]
35. In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender.
Zgliczynski W; Kochman M; Misiorowski W; Zdunowski P
Neuro Endocrinol Lett; 2007 Oct; 28(5):621-8. PubMed ID: 17984937
[TBL] [Abstract][Full Text] [Related]
36. Re: hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids.
Seftel AD
J Urol; 2014 Jun; 191(6):1841. PubMed ID: 25280309
[No Abstract] [Full Text] [Related]
37. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.
Fairfield WP; Finkelstein JS; Klibanski A; Grinspoon SK
J Clin Endocrinol Metab; 2001 May; 86(5):2020-6. PubMed ID: 11344201
[TBL] [Abstract][Full Text] [Related]
38. Bone health in hypogonadal men.
Irwig MS
Curr Opin Urol; 2014 Nov; 24(6):608-13. PubMed ID: 25144148
[TBL] [Abstract][Full Text] [Related]
39. Sex hormone suppression by intrathecal opioids: a prospective study.
Roberts LJ; Finch PM; Pullan PT; Bhagat CI; Price LM
Clin J Pain; 2002; 18(3):144-8. PubMed ID: 12048415
[TBL] [Abstract][Full Text] [Related]
40. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
